Market Research Report

A quick peek into the report

Global SERD Therapeutics Market

Focus on Product, Therapy, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030

Some Faq's

Frequently Asked Questions

The global SERD therapeutics market was valued at $1000.2 million in 2019 and is expected to reach $4085.0 million by 2030, witnessing a CAGR of 16.66% during the forecast period 2020-2030.

Several factors favor the growth of SERD therapeutics market such as the increasing global breast cancer incidence and mortality and rising demand for endocrine therapies that cure chronic conditions completely and improve the quality of life of patient.

The North American region is the leading contributor to the SERD therapeutics market in terms revenue due to the growing breast cancer incidence, relapse from existing endocrine therapies, and the substantial R&D made in the field.

Market challenges such as the resistance to endocrine therapy are impacting the growth curve of global SERD therapeutics market.

The key players operating in the global SERD therapeutics market include Glenmark Pharmaceuticals, Sandoz, Accord Healthcare, Dr. Reddy’s Laboratories, Teva Pharmaceuticals Industries Ltd., and Mylan N.V., among others.